Internal Medicine, Hematology & Oncology · Los Angeles, CA
NPI
1437268174
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
1245 Wilshire Blvd, Suite 303
Los Angeles, CA, 90017
Phone (213) 977-1214
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.4M
68,780 services
Medicare patients, 2024
291
Average age 74
Drug cost, 2024
$3.8M
1,326 prescriptions
Company payments, 2025
$7,956
From 41 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Lasika C Seneviratne was code J0897 (injection, denosumab, 1 mg), 6,674 times for 47 patients. In total Lasika C Seneviratne billed 68,780 services in 96 codes, and Medicare paid $1.4M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-03-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 6,674 | 47 | $20.27 | $135K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,671 | 39 | $0.09 | $236 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 1,800 | 18 | $15.84 | $29K |
| J1642 Injection, heparin sodium, (heparin lock flush), per 10 units | Office | 1,360 | 17 | $0.01 | $17.34 |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 975 | 13 | $6.16 | $6,009 |
| 99214 Office E&M - Established | Office | 945 | 205 | $101.44 | $96K |
| 85025 Blood Count | Office | 721 | 118 | $7.61 | $5,487 |
| 80053 Clinical Chemistry | Office | 428 | 91 | $10.35 | $4,430 |
| 96372 Injection Administration | Office | 420 | 83 | $11.93 | $5,009 |
| 36415 Venipuncture Blood Collection | Office | 409 | 118 | $8.63 | $3,532 |
| 96365 Intravenous Infusion, Hydration | Office | 246 | 40 | $54.09 | $13K |
| J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) | Office | 219 | 35 | $1.02 | $223 |
| 96127 Behavioral Health Services | Office | 219 | 161 | $3.09 | $677 |
| 96367 Intravenous Infusion, Hydration | Office | 212 | 39 | $24.20 | $5,129 |
| 96361 Intravenous Infusion, Hydration | Office | 174 | 20 | $10.56 | $1,837 |
By year: 2022 $710K for 69,174 services; 2023 $995K for 86,648 services; 2024 $1.4M for 68,780 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 721 | 118 | $7.61 | $5,487 |
| 80053 Clinical Chemistry | 428 | 91 | $10.35 | $4,430 |
| 36415 Venipuncture Blood Collection | 409 | 118 | $8.63 | $3,532 |
Medicare prescription drug claims, 2024
In 2024, the drug Lasika C Seneviratne prescribed most often to Medicare patients was Anastrozole, with 248 prescriptions and refills. In total Lasika C Seneviratne wrote 1,326 Medicare prescriptions that cost $3.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 248 | 565 | 66 | $5,099 |
| Alendronate Sodium Generic | 92 | 220 | 27 | $811 |
| Procrit Epoetin Alfa | 72 | 73 | 21 | $200K |
| Letrozole Generic | 68 | 166 | 18 | $1,632 |
| Revlimid Lenalidomide | 45 | 45 | Under 11 | $705K |
| Ibrance Palbociclib | 41 | 41 | Under 11 | $601K |
| Dexamethasone Generic | 32 | 48 | Under 11 | $878 |
| Kisqali Ribociclib Succinate | 30 | 30 | Under 11 | $517K |
| Hydroxyurea Generic | 30 | 62 | Under 11 | $845 |
| Lupron Depot Leuprolide Acetate | 30 | 43 | Under 11 | $84K |
| Zarxio Filgrastim-Sndz | 29 | 29 | Under 11 | $37K |
| Abiraterone Acetate Generic | 25 | 25 | Under 11 | $27K |
| Gabapentin Generic | 22 | 34 | Under 11 | $154 |
| Deferasirox Generic | 22 | 22 | Under 11 | $7,152 |
| Prednisone Generic | 21 | 23 | Under 11 | $111 |
Brand drugs: 430 claims; generic drugs: 896 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Lasika C Seneviratne $7,956 ($7,956 in general payments such as food, travel and fees) from 41 companies. The largest payer was Novartis Pharmaceuticals Corporation with $2,699.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 30 | $2,699 |
| Abbvie Inc. ABBV | 13 | $1,384 |
| Janssen Biotech, Inc. JNJ | 11 | $297 |
| Pfizer Inc. PFE | 13 | $292 |
| E.R. Squibb & Sons, L.L.C. BMY | 15 | $274 |
| Daiichi Sankyo Inc. 4568.T | 16 | $273 |
| AstraZeneca Pharmaceuticals LP AZN | 11 | $272 |
| Caris MPI, Inc. | 3 | $210 |
| Genzyme Corporation SNY | 5 | $203 |
| Celgene Corporation BMY | 12 | $198 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.